维美德医疗报告了2025年创纪录的业绩,并在2026年3月启动了5000万美元的股票回购计划. Viemed Healthcare reported record 2025 results and launched a $50 million share repurchase program in March 2026.

富有活力的保健机构报告了2025年创纪录的成果,收入2.703亿美元,增长21%,净收入1 490万美元,增长33%。 Viemed Healthcare reported record 2025 results, with $270.3 million in revenue, a 21% increase, and net income of $14.9 million, up 33%. 该公司在经调整的EBITDA中实现了创纪录的6 140万美元,在自由现金流中实现了2 810万美元。 The company achieved a record $61.4 million in adjusted EBITDA and $28.1 million in free cash flow. 2026年3月4日, Viemed 宣布了一个新的股票回购计划, 授权到2027年3月, 最多193万股, 约占未清股份的5%, On March 4, 2026, Viemed announced a new share repurchase program authorizing up to 1.93 million shares—about 5% of outstanding shares—through March 2027, citing strong cash flow and a low debt position. 该公司预计2026年的收入将在3.10亿至3.2亿美元之间。 The company expects 2026 revenue between $310 million and $320 million.